0001213900-22-024490.txt : 20220506 0001213900-22-024490.hdr.sgml : 20220506 20220506145047 ACCESSION NUMBER: 0001213900-22-024490 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220505 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220506 DATE AS OF CHANGE: 20220506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 22900546 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea159542-8k_inmedphar.htm CURRENT REPORT
0001728328 false A1 0001728328 2022-05-05 2022-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 5, 2022

 

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

 

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction
of Incorporation)

  

(Commission File Number)

  

(IRS Employer
Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

   V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On May 5, 2022, the Company announced that that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and weight/BMI.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description
99.1   News release, dated May 5, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)  

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: May 6, 2022 By: /s/ Brenda Edwards
   

Brenda Edwards

Interim, Chief Financial Officer

 

 

 2

 

 

 EX-99.1 2 ea159542ex99-1_inmedphar.htm NEWS RELEASE, DATED MAY 5, 2022

Exhibit 99.1 

 

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed to Supply Rare Cannabinoids to Radicle
Science’s “Radicle Energy Study” to Assess the
Health Effects of THCV

 

●Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedica
   
●Assesses key health outcomes for energy, focus, appetite and weight/BMI
   
●Provides valuable evidence-based data on cannabinoids for consumers, brands and healthcare providers

 

Vancouver, BC and South San Francisco, CA – May 05, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and weight/BMI. BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie.

 

This rare cannabinoid, consumer-based investigation will measure the effects of the Company’s d-9 dominant THCV in a randomized, blinded, placebo-controlled study in up to 900 adult participants aged 21 and older who reside in the United States. The study includes three dosing groups including a placebo group (no THCV), each delivered via Trokie’s proprietary lozenge technology. The study is set to begin participant recruitment in May and will run for a four week period starting in June with results expected during the summer. The study is part of Radicle Science’s large scale investigations into several rare cannabinoids involving up to 10,000 participants in total, the largest of its kind to date.

 

“We are excited to be part of this groundbreaking study with Trokie and Radicle Science in advance of our commercial launch of d-9 dominant THCV. Radicle Science has been at the forefront of cannabinoid research, providing much needed scientific evidence to validate the effects of cannabinoids, and Trokie is a leader in unique and effective delivery systems for cannabinoids,” said Dr. Shane Johnson, SVP and General Manager of BayMedica. “As a company driven by data and science, independent third-party research provides important information as we continue to expand our product portfolio of rare cannabinoids for the health and wellness market. Evidence-based decision making is key to facilitate adoption of rare cannabinoids by consumers, brands and healthcare providers. This research will advance the understanding of rare cannabinoids, which have been historically under-investigated.”

 

Dr. Emily Pauli, Pharm.D, Chief Research Officer of Radicle Science, added, “Consumers have been reporting anecdotal benefits from THCV; but, to date, we have sparse evidence on it and other rare cannabinoids. We look forward to analyzing the results of this inaugural study of THCV, which is the first of its kind in a consumer-driven setting. With the large number of participants, we can assess whether there are meaningful improvements with energy and focus, as well as any impact on appetite. With our innovative AI-enabled approach, we can study diverse Americans across the country - which may also reveal personalized factors that impact the effect of THCV.”

 

 

 

 

“This study continues Trokie’s commitment to developing products based on scientific evidence and rigorous standards” said Gavin Chandler, CFA, CEO and President of Trokie. “The Radicle Science Discovery platform is the gold standard in the health and wellness industry for understanding how cannabinoid products can provide health benefits across many different populations. We are excited to partner with BayMedica on this study, with their differentiated rare cannabinoids of exceptional quality and purity, which matches our product philosophy.” Trokie’s Advisory Board member, Jordan Tishler, MD, President of the Association of Cannabinoid Specialists and faculty at Harvard Medical School, added, “The Radicle Energy study will significantly add to the body of knowledge regarding the health effects of lesser known cannabinoids like THCV. The combination of Trokie’s novel delivery system, BayMedica’s high purity cannabinoids, and Radicle’s Discovery study platform provide an excellent opportunity to learn more about how these products can improve human health.”

 

BayMedica – We do cannabinoids differently

 

BayMedica manufactures rare cannabinoids through novel synthetic methods that ensure reproducible quality and purity. The Company’s products are manufactured under food-grade GMP (Good Manufacturing Practice) standards for the health and wellness sector, and are bioidentical to plant-derived compounds. These cannabinoids can be custom formulated for a variety of consumer health and wellness applications including supplements, nutraceuticals, cosmetics and animal health. Utilizing reproducible processes guarantee the purity and consistency of our cannabinoids each and every time. Furthermore, these production methods can be scaled up to meet demand to ensure that clients have an ongoing source of cannabinoids without supply chain concerns. BayMedica has large scale batches of cannabidivarin (“CBDV”), cannabichromene (“CBC”) and cannabicitran (“CBT”) available for wholesale purchase and will be commencing B2B sales of d-9 dominant tetrahydrocannabivarin (“THCV”) soon.

 

About THCV:

 

Tetrahydrocannabivarin, also known as THCV, or d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better known major cannabinoid, tetrahydrocannabinol (“THC”). While these two cannabinoids share a similar structure and name, they have very different physiological effects. Notably, unlike THC which is intoxicating and produces a “high” or euphoric effect, and is a scheduled compound that is federally illegal unless prescribed by a physician, THCV is non-intoxicating and is not a scheduled compound.

 

Learn more about InMed’s Cannabinoids in Development: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/

 

Learn more about BayMedica’s THCV: https://www.baymedica.com/tetrahydrocannabivarin-thcv/

 

Learn more about BayMedica’s CBC: https://www.baymedica.com/cannabichromene-cbc/

 

About InMed:

 

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica, LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com and www.baymedica.com.

 

2

 

 

About Radicle Science:

 

Radicle Science is an AI-driven healthtech B-corp offering the first ever scalable path to validate and predict the effects of health and wellness products, transforming them into democratized precision solutions for ailments or enhancement of human function. Radicle Science leverages a proprietary data analytics platform and a virtual, direct-to-consumer (D2C) clinical trial model to deliver objective health outcome data across diverse populations and conditions—all at a fraction of the cost and time of traditional methods. The Radicle Vision is a future where affordable, accessible health and wellness products are trusted by patients, recommended by healthcare providers, reimbursed by insurance and used as widely as pharmaceutical drugs. Learn more at www.RadicleScience.com.

 

Investor Contact:

 

Colin Clancy

Senior Director, Investor Relations

T: +1.604.416.0999

E: cclancy@inmedpharma.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and weight/BMI; supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie; a consumer-based investigation will measure the effects of the Company’s d-9 dominant THCV in a randomized, blinded, placebo-controlled study in up to 900 adult participants aged 21 and older who reside in the United States; a study includes three dosing groups including a placebo group (no THCV), each delivered via Trokie’s proprietary lozenge technology; a groundbreaking study with Trokie and Radicle Science in advance of our commercial launch of d-9 dominant THC; Radicle Science being at the forefront of cannabinoid research, providing much needed scientific evidence to validate the effects of cannabinoids, and Trokie being a leader in unique and effective delivery systems for cannabinoids; independent third-party research providing important information as we continue to expand our product portfolio of rare cannabinoids for the health and wellness market; evidence-based decision making being key to facilitate adoption of rare cannabinoids by consumers, brands and healthcare providers; research that will advance the understanding of rare cannabinoids, which have been historically under-investigated; analyzing the results of this inaugural study of THCV, which is the first of its kind in a consumer-driven setting; a large number of participants, we can assess whether there are meaningful improvements with energy and focus, as well as any impact on appetite; an innovative AI-enabled approach, we can study diverse Americans across the country - which may also reveal personalized factors that impact the effect of THCV; developing products based on scientific evidence and rigorous standards; The Radicle Science Discovery platform is the gold standard in the health and wellness industry for understanding how cannabinoid products can provide health benefits across many different populations; differentiated rare cannabinoids of exceptional quality and purity; significantly add to the body of knowledge regarding the health effects of lesser known cannabinoids like THCV; combination of Trokie’s novel delivery system, BayMedica’s high purity cannabinoids, and Radicle’s Discovery study platform provide an excellent opportunity to learn more about how these products can improve human health; manufactures rare cannabinoids through novel synthetic methods that ensure reproducible quality and purity; manufactured under food-grade GMP (Good Manufacturing Practice) standards for the health and wellness sector, and are bioidentical to plant-derived compounds; cannabinoids can be custom formulated for a variety of consumer health and wellness applications including supplements, nutraceuticals, cosmetics and animal health; Utilizing reproducible processes guarantee the purity and consistency of our cannabinoids each and every time; production methods can be scaled up to meet demand to ensure that clients have an ongoing source of cannabinoids without supply chain concerns; being a global leader in the research, development, manufacturing and development of rare cannabinoids; and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

 

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

 

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Security and Exchange Commission on www.sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

3

 

 

 EX-101.SCH 3 inm-20220505.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inm-20220505_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 inm-20220505_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 05, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 05, 2022
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street
Entity Address, City or Town Vancouver, B.C.
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code (604)
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea159542-8k_inmedphar_htm.xml IDEA: XBRL DOCUMENT 0001728328 2022-05-05 2022-05-05 iso4217:USD shares iso4217:USD shares 0001728328 false A1 8-K 2022-05-05 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street Vancouver, B.C. CA V6C 1B4 (604) 669-7207 false false false false Common Shares, no par value INM NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea159542-8k_inmedphar.htm ea159542ex99-1_inmedphar.htm inm-20220505.xsd inm-20220505_lab.xml inm-20220505_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea159542-8k_inmedphar.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea159542-8k_inmedphar.htm" ] }, "labelLink": { "local": [ "inm-20220505_lab.xml" ] }, "presentationLink": { "local": [ "inm-20220505_pre.xml" ] }, "schema": { "local": [ "inm-20220505.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20220505", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea159542-8k_inmedphar.htm", "contextRef": "From2022-05-05to2022-05-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://inmedpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea159542-8k_inmedphar.htm", "contextRef": "From2022-05-05to2022-05-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001213900-22-024490-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-024490-xbrl.zip M4$L#!!0 ( %9VIE34WXJ2PQ0 !F1 9 96$Q-3DU-#(M.&M?:6YM M961P:&%R+FAT;>T]:5/B2M??K?(_],NM^Y36E25A$5!Y"MED%/0*,^/XQ6J2 M1EI#PG0G"O/KW].=A#7((BHSC]Y%H;?39S^G3SK'_^UW#?1$&*>6>1)2(K$0 M(J9FZ=2\/PDY=CN<#OTWM[MSW+&A'_0U^4FH8]N];#3Z_/P<>8Y'+'8?53*9 M3+0O^H3<3ME^8#\U%E.B-[6+AM8A71RF)K>QJ9'A((.:C_/G%ZW#KBUFT(FN MXAM_D7AT9FIHU4<#QCNGHF[C1%<[L&O2[6K[72FW$JIR^!(<;H_A@/Z\OHJ M&79(;DZO+T;=[>#^HZY1FV&3MRW6Q3;04,R4#,?4L)H:FR3,B38Q$7R.W%M/ M"^=)A^.*/\\,<29W*II;F \QKI,I=/MK0@.,4)6?";\K(^VY$Z>BT.IW='CX M'N/>L',;\Y;LZ#7(><,Q90QJ:&&607C@&-D2,$BS'--F@V#XO48YS!_ F3V[ M 'P9,'>U7AMVI6:7Z+T.!J1'-*LK>JNQ9"P9DB)'L Z_D?@YMJEMD-QQU/T- MK5UB8R2F"9.?#GTZ"14LTR:F'6X.>D #S?UT$K))WXZZDAD5XZ+>M,?_%PZC M,B6&GD4-8A^A.NZ2+.KK_2-4+B?UHSL)E]^M,D]1P'+ES16? 6GNY"U+'R!N#PQR$FH# V:1$NO9 MJ$F[T*5.GM&UU<7F@?O% 0# :%NRNDZ?_'$ZY3T##[+(M$PB&VD_*WB6,"$, M\A/5=6)*T1 ?H6/=Z<)YGH1 (6=;%J@>;$HV&8=G@HM".=F^01"H?A("&JM4 MD!#VJ,[BH@KFG_4L)LU P\8V*;@*KV#I0)"\$@A.=((N CI0VX2!+T&XVT/8 MARR7AA_ 1-*:9SM2]8.&"/MB'>ES/>2UVJ#*3D*<=GL&<=67M]+DW.YJW'*8 MOQATDSR:]? B]_T"7GPUZP\C$A/#;X??4UVTM"EA2.Z$!!K50O5\DH.F!X^6 MBP:NYZW6 _1:^BP4X-DPNPB$R8VVX,\T:IL9!HPU9Y#?,@W6! #^EQY*)_'L MF-1%,JB'&6QV">8.(SE/CV2ACS^9WS2YA)AMSORN4IJ[A(<$V6GM-4;*;V8= M4%1 QEG)E>-VABOWT""S,( M]21T3!Y=[>#K\.,HC(??XI_CGJ_W!4^%L4'OS2S20!X(.T)=S.ZI&;:M7A;% MAA];EFU;7?@F!/Y03TXT;M:N'8.$K_"]M+[CEF7!;$?HF>IV1]BLV-^AB9$M MBP'H[LA3 VN/2 6SQBV#ZD?(:_3G<=N54;LPA&%.?X&9A6]A8M[#YKB5#+=Q MEQI@\1;8R?_\I:1B1\=1,3[G(M'[_]CNHQ/;WP2*-P1NSZ/X.$">CY!>Y"/X M<$D09W>Q-I"3Q$E(ZK1R7^O59JFXN]-HYINE!C!O*S>UBVW?0:-4^'I=;59+ MC=V=?+V(2C>%LWR]4D*%RUJMVFA4+^M+;4O=CFW%O&U]SS?.JO5*\[)^L+M3 MC!0B"#R&1&:9G2@K[&33//_NRDF))+=1_:Q'BJVDZ);+?_GRN@90RBD]C_\N M$TO(8#4<+EJ:(R(,D2BXTX9Q]2C"_F7-66W84H>(/3F,VA3&E_I: M!YL@!GG-1E8;*9EX8JFM?9AX!&_MMY47D??8W0',7Y.>Q6RT)[X0E" 8@EK" M;42>8%W$9#/1][-HVJZ6INSJEJ8\U<"/$#H5*+UA=F&R ,$>-'M%$*EY'U$2% M#@;5SI;S*;9.WZT93W_JMFVAZK&-6P8!CC<,^%Z3E3>QD/S(.)79'J>C!]\X2SP19E,-&[X@NTU! MPCV$,*[^O6&O;EKGEB=T[HLGG'=Z_R)8#7=_*H/>S6'ID#R&D*S#. EELS?% MFVPVKTQM0!3W-[U64%+6ELS%:/UA3'RDHX MGDFED\M8Y4_>^6#>R4_P3A/WJUX-@"9USTN,]$4K.U^OBOJ/G^N'B-.,- > M4"Z3#BL)-:T>9I9D*_@?FV\XEB /> :PK2DSO"5I=)^:>](VC)^J+_ZQ&+JT M.X2A+PZC7*W7<8E[UR@H3M=&$G=J?)\TW0::5J\;JQ&SU.T9UH"P=<1Z4O^BNA4)9 )/O\(O$1M,Q2Q; M$HF\0WP19+P7>"N)S-^S++=,(N(]JV.".;%JUHB^&CM=R;)JC3@2)5R8C,AL M&D/B_;=$R;PS;->?R>LZ(YQ[ORZH291@9ZI>_58\9*U6XBRU,6C:#"=>P M'FIGBJ&8$QR, M$>1__DJKRN$1"(9-#-+K6"9!IDP)'""0$,,15@9A1C"H()W,UIPHGK(33DP> MNLU7;XGH#ZFU\O5!N+Q5+[,_19#,@ISV0+RQ@]2NQY9?2GY6' MQH_+PJWVD-B$5IY>,Y1+I3+A0S5V^#L>;K^V!&O+ *];]NX.[O4,T($B_;#$ M%K8MA50&%Y8PO]* (?HM7"^)66HR*$LR6U4R!'>@.L%J@ -^UJN5.R M81$4$&!1'N0UMBT#5A<# :@G*G+^'.T=TQPGXHGL'*H0DS!P9:LFS.'( M@QZ4CZ@1%^S][ *$ISX(W]M<@^(O$!B:S'C8?FBYV!_LN/?/[E[/R[2^>(ANI[IUW5T @2(+ F<-$XFBN9Q,0LVP0?QY0L-%Q MJ%#/*^H7HBIT+$JH25?HA+"Y@(S5Q8MR^#WE$!7*UTB-QR+0>Q\M"$\^1, ^ MY6E%>?)+L1I@WC4JDN(U4/>@\XU@82IJ3MQ^LIXJM&_$WE:CY<'VT9 %D86T,M(7&2DGH876OM>\",Q2VE^3, M'? I:7^"I"6"):W*N4/80GDK7#C=/NF1>/UMW<%%T/U^4AMH+4>0-6 ME;K_P4 ?SU3,UV7^@=0:I[1; M4>?<%$\_#$_U"-8Z2#,PYRM7GWL'Z-M[*/XR6E\X:GQ%QGK3Q&)8X'SM@M75 M?QJ#;LLR]OAZ]:U;SQ-;(8+BJ,'=C=5V?PLQ]/[R#*0GH29Z[E 0T9&:?ZG, M8(@'V/<]L\#L"@UGL2QB]ZT]-98X4./I S69W _07Q]SE#VOU,PS<0-%;4F- M%>R?<>5OXY[R2B(9M@2VI M8?9(;'1Q45BBYN8S5 %@JJ8NHD2"6@.DN<>%,.TCF#4BG[6:.LNC',$Z$&.* ME>\1&+%GNR.BS9[W]+].VM1TG_UWSR)B23^PF3J#<*_DB:,]@8_#(_X.$+\G[PZPF!>TJJVP&C!;X$T_PVE%\#H:"!OPYXUL"0FVBA]*DZ0%*OAE M50)(#]0YV5*W0-.?H2(G\*JR@E5*K/=\.#A[IH/Z^B7H >D;FSEDMG T$"XO M<9-:F+CY9)&1RFB/ZX#=G4DE(*KLIE0*DAJ%SA0&=$!?$(-H-N@+TY)I$8<3 MV0LH[Y4?B%=G4%D X%Z9+0@NUS(&@DV?*2P-R^[NF O-#'R1#D,!#6$34T< M[&!-EKV+WN+%)3IF.G<+#\0"\Y,R\3T\3,J,JYC(2[*@3,I"OSF$W[TB*E@0 M;I2TVM,>XFKE3=.8\X!:.GWY!TK!AU5B+;CF6MWB.JV/I+=7[S4&L #U",;\ M=$3Z&\!SX99>[RP)7D@^C)-79"QG*)R2V%_^TN^ *2;"A5[.O[!]!EA&\&.X M14"J84<]N(!#Y#;:Q/+Y7.;:8!-0@[?457T!H?&GN[HQ= MTG@@C?SP$C/3!(=!$]Y'!]MH8E4O7_<7C()_0CG9@]H<<:?%J4XQ P_H% ]J M1#A!!V 1# .UB.=O"!^$84:0!FO@%C4MJD.D(UP:X?F(H G#.(AU&AH5VNQ M/G;L/],P;"V9X'P-9J8"(!U](#P9S#GAW'6EVFUP:[CP9'1BV#B<$;%1&ER/ M(SVOM1S>QE> M)H*H.7P)'>+$%CXC>,] 6QD7"W6$A#8:?U"FU._0EN#O3"8B&C@PL_B^[3"3 M\@[(B* N[V!@<^'# ZOK!&(#'7GLTJ8&T3U^$0O*8]">!>PI.-+SN)&27C*N M/Q!)!MQU@X,],'KB"\T.'5,_"A!8'+\(U+HNC:0K).6N9>O.+JT>E\< 9E M'"5RQ],!RP&$4QH!5H1^+D0M$6'UQ ,4HI[;W]GN#D1LW+V^44/C8 'J- BS M/(BV(W'R;K"J MBZT+!3X*&'%'NH^GA:4:_XL(:HX_X[&[0WP;,E0^GBH$;0;GF%'O+$R 6T;D5>6>6B;+H4(,"#JY4IG"!O$N?"<4B._W.;+=) MAY+Z'DV EF4DF5-+/9,+*Z,6] MD8[=#>5@0E$J:!#,(>33I6LX\0X!O"D*?N]0F[P-V918XL\@6L$"9,JT(D3? M-F%8D[=I%+&-W2L&]TBW1701@8CC!QD/>,?L5?G2;R3>^@T1M?MN"&G5W A! MA$M\&",H,64?N5M:] #6MEF_]WDSQ'1F5SU"EU*E\:Q8QPL>C] W4>OSCHG? MY3>]=@YV\FW2+@*.D'C/5Q;E&<2MFO^":8&DNB6VKDRD:/U1\A#C?S[5_,*A MS<>]X.ICW^'0J%;J^>;7:_$JRPU!NP6O0?VHF.=J[!Q9F@,&\D>9%UHOF]P* M."'7'6. -.QPF8^FW'M?DA<\<< U-%BF3$*W"$18;7'P+B:2B2.WP^Y.AS#B MB/R2G \[=L=B8//TA M)/]'>12=,F+JV'NL6W\6=4$?0YPW"6P63/I!9M+%^0RZ7W/9ZV;*8,4M %WO MCMI"AY(V&N7(W7L4V9R;Q%\?IVVCV[3J\]:_)=AS:&8 M3[+5"\VV02*B+4L?B.<$HAV[:^0FD=L@MA^ ]_7^$:H6Y1]WL?3IG2Q>=2^U MDAN3X\B7?OE!+YW?/^;_O6Y%\^W^@_I=LY3#VME9K] 8%*JFI6N/?<.\/KLU M"&O^8SVIR6NK4OGQX_!!^=7YMU-N=I[T:JUN?+N^?7YFM\PHU2S^];:BQ6Z> M!A?XL'SU[*0QMG^H-QJY.LP_% =%\]'H:C\KZ5K9.FNURN?5KZP;NZF2_N#4 M2#EZ_R)Q_F3V*CW]QTT%Z]_SM#DY+3%?:6YM961P:&%R+FAT;>U=:W/;.);]KBK]!ZRG-I.N ME>1')^GQHUWK5Q+/)FEO[$G7?-J"2$A$AR08@K2C_O5[[@5(D9)LRXGD]&0Z M7>W(? 7%_=Q[@/*P>NKMV\.NYV#UV='I_A;T)^#J_.K-V>'!YON;]S=]+XO/KGF[.?-T8F+?;$]E96B"N=*"O>J1OQWB0R[;D+/7&I*A[^V+1.9CG>X)>G1KL$,_Z?]]4:C/15_&>HR;N1Y'Q<;AP?'AV>=(#W4A M=G<'VT_2H-K0W^_>+H]+3ZW1-SH\,B(FJV_G-?+$_9T.2ARON!B6.9604J_*<-EIV# MJ_?5!-YVM9NU'OU\7JACPX?_M*7+X_^7E#?=[=[6__W];6]N"W;+PACMY<_;SA M-@RJ=7HK-YX_^R;<6*Q5JV/-;5K[[NCR].A_]\3YN[=3Q5GKC+-:NK[)+DM= M*/'C]E;_;]O/Q:\#\5K: AMHQ64Q6/?D'V0:F!**V!/')SUQ(E,92O'AQ8G8 M/GZV[LFO5+PG_FM[\&+KV>#%B]W!3SM;/ZU[SK-$:LRJTY'Y;YTF*LPBF2=R M$)ADW5/?W-P,%DS)>HX?[YUYW&0;??@(7J%IV.:G&YHX%-M_6W;./HPWSUM? M&)JB,(F_MM KO?SEW55STOY()CJ>[-TW(S]K]>_*,67C\#Q]J\)NIS#BLLRR M>"+>RUR1,*=RJ%.C0PO?@HNA#F)U<$R?2K-OQ9,XI _^&7&6 MJGP\@0:6X>1)SK=HB"-KE<5@D1_EM9)Q$8FST4@%A15F)*Y>GWPXV*25W>K> M'\C9A2*U>AY6TM F?0H8F@!A%D#\>GYZ]?KG#4(*&U\JM'<*$!9Z+VR8=Y([ MVX,?^5W6L+G;V\\&V\_Y_NJ8^)?=%S_M3KGHYEWA!/!,!^>'+)8>B"_YYT;' ML2BM$J&*"]G?%:%)="K3@B46+$_+D0R*,E>A&$X$:U2M'+8<6AUJF4_$L9S@ M#M@/2W5^Z/QC8[%DQI;:JO5)[LIY_@W&K[S!0_Y,/<>?>OL'U5OG/I1]V-9^ M5!,1.4=CR@*H 3./3"X4^Z@>/@KJY-85I!#F+-R'&U(10E,V:B5>;@)2QB)"YE M*EZ"K8&V@4$4>R2>I*&TT7ZW\U9.Q-;SGMC9VMFIK@IL/0,<<<&16*!*U@(+ MV!,,B/GBJ8\'/ YR 0#V$(-BUBDV6 ,/W&L@+,3^O"18>DA)H+/UW66B($^**G(2D M*58]H:W(, ?)'4(3W#(E)!&3R4+HHHG:>E/8UNMV& H.*Y&C6><&9YDEM CB MJY#(1TP]9E(-#6<"IMF1A"6HRO35H9-0+ESJ=K"N"HY6# _[NS5':XA:J"*7 MT23,C1_Z6H);]3N$8.N7P*Z68]R410%&@XVWNLA!M^/Y(T7%',N!)#&'6!GA M4825&>"Q"&?!,TV4)V4L"^R$3FFMQ-LLUZH@R!R;WU4Z5G,8^RHW'[4:K$EC M?BMMH4>3^\+\E>CEZFS)5:0A%[-2U*OMI[>S.KU66-[8J0?O60)-H.UI"!CI M#?U::ZJ7V;D=)#&7@NPRKOZN,-\PUFF(#]U.%L,^#$T?%!2YB6-5R33>*3.2 M[-VM+2'#,BY$)LF=:DR&R>48C^YLLZPAXHI@HOP#> X=@: M*]3G##)!/IHM;;=#_(=,0:@&HD47D4*B,V/XZE7&4 <\#H>AVH)HG?9;F/=< MQ@NL*IXV\361Z"1G>ZNWM;4%&6O*#8F&*63<8PGAR2S30X;H(\22W@30(,NQ M3I?[F ;$&_)?89G!,_4Y8+5@X:BWHX!I8*%,PV&NY$?>1+=IO-%.%EE29G:. MU3N\EO01 Y'<3'TL. RW&=&-.;LPF!LIDA8T*8Q7\/9 %-4H!R/8F34=W]3= M3_UL4F*B5*F0C B-" ;KH :1M& @2TV;.VO'VJZ?%NG7"Z8TH$:W4Z;Z4^G8 MX%Z'NE9:.Q%V8@N5>$S:'++".%:"]E.HQ&4DH4)_-U%JR75>?KC@,5^1D]D588ZY4_)X#(]I%%MA";*RF<(/\O*1SL,^ M;?>DYEZ%BZ$626;R0K))('_K3#^VXT:1=X#BE\Q Z#E;7&PRW@W+ %M#;XY, MK,U"),7,(';[(-N!@SA.":] =#^J8B#.9H"^ M8D A(61-H%"M,Q/SR\CC49 M=,B([L# DTF?D1,6%+&/=<]!_<(IH(=(*QKYB M["\CJ*3*69_GH*\,"11,(P"_>\Q29Q=R1<+FH+P*0C+DN)&J$5EO6(J$#0@+Z;?3J!)@MMO1A8,0V.1\?E,' D8S-N8C2?&-S'TL(./) M[T0$24;E 2L;"OM6CDM28F<]?=6B$@_M0/I(YVVW TH()=5(S*LUO#@M%W20 M$:Y=EDC+9.CL0].[\5)!?Q4.W$2*UT4_G/$'CDLQWJB,2>4A_HIP@'4VWB%[ M&!3&AS (0P$'04G?_+UYJ%8=[4+VQVL<@<%"0;LPE^OVJ MY'IZ_J$BI)G%VMY9D,9Z0==\GTEU[1BP]:/8'CP'31:V/@0)%^T1??YKNOZ# M3S005!-1<,<(77)T_(N'G_#D_*/ADZOPA4D:T >0;(D>;" MK["2MH5W7DF [=3+T#-8<13RD(Q MVD(H51!6J6SJF"J_%0E5#+@(=<#<8L\P N=A6IX],C=-!P!P4W&!3)?'"]6@ MM>?QIBMA/*9A=G):4&8R2EM0Z,)^9 9\D^%.*6XE^SDM_)G4^1'>MYZ[BX5H M^,QZ:,W)D'FH!19B L6P"%;R4PFI*%QXER$N*R:]VIX6001A:. XD44Z-M9D MT:0RE;.R:VO(+A\;8G&BR GU &/S$-RYTC;B#7X+O]_:5]J((VL-(H(* ML37:!\0E8D?*Q]G"(308=+C4"44!KV5^35,YYL20@LB8N((*"P7%Y\JJV 7. MRT(U2&KA(H%0\"JQGV@:&N>@/Z;F!KYJ3-Y\C.DJW^[WN1$HQ%1AROF%=AZZ MVXGU1^7CFBOV80ENU>N=824\I8IG X=&(K%^D')C?O,61"E^S?73M7)4L5NM M(Y7H8I](1.*8MR8C.(68IF!PC3@G!^8VA!6&IBQ8&\ 'JT1+#3QR$%$)B?=, M6KE[?31/>GPX5;XJA?TKI7#:NE4K7SQ9:7?IMP/MTV4W]#$[5)3+!ADE1SA4)(UH*S^IQ1 7L7T(0AH9:Y=-HXRZ*MC65 A_ M(4T RS'FK])=5=J0T^4.J?< _8M\6E2AY*U-:#?8=A)XUPD6X+52_*- O,S! M2FMC\#'@8KD8EQ*Q<:%4;_/:+%/V+W1FO?^TZ,^=7"?>ZYJ-G!%FKA9>ZR$$Q : %5Y/%+A19<\-6+$/=BA281E3PVV] 2ZQ M8=V3(Q4JMU4P T"K,1%'OB.#\PYR/73E3^D6!5Q-LL15.$*=:;])<6ONU!3- M^>O]_]6Q17F777^5 NYV96LJ>:+5"_P%)7T_S M\RHIG&N&XACXZ+PJX#MO1&UZXK@?F#R#-QDYQS#M Z ,&F>@./4#EQ"UFI5< M7$D&NG#-SHV"Q*(L8I5-A5O.96K)'_CY$M=#%ZK$!#E\!)7/,;+OMH$-*EWJ MD;.6.G:] 7P8)J)6F,37F,.@YMMB[Y%2<833EC6 MU0G.P<);Y45)K7FA!DT%3$._=OY/3W=.?JC=-A9&S66)@9_U=4OVM\(,?_-- M6>TS/7YF5Z>K>@\:!;HJXQEJ_O5)PG4 29T/%!6/.+?LL))K4+"N;X2RGGPQ ME^Y5RA_X+*=+=5>L^>!XS AN5')FXL:U98Q&5#_#SO= (&5E.4-[U\9ROAKX MR!8NV*] 1(^:.SDK&%("83A9V.Q$3^ED6.;6O:TITRJK8FY)5ZGM \]2M M@CB:X4LAO(H2F/ +]J+ Y[!7IFTK;\IUK/IW':BJW!NFS:(N&:/5U"T2[UT?+)*>XZDG O MW?"[:R^9^F^5:FUY_5) MF.DH+K^YQ\U4W_1,'-C:[7RS,W'=SO10G#=X^PM.(S55:O7GY(!.%QZ4JPF2 M]Y#T-6?%NIVO."PF5G%6K-MYR&&Q^[GQ9:>_NIV5'_]:FN)'/>.SI)C[V>KO M#:K"B:$BMMW][NQ1H9END ><%(*E_IJC0@^AN9&\GYXHJN+ZI8X4+EZZ$F8;F>9HS#BKI,P2]NYF7,R M[6.@*SDH(Y8X)]/M5 A@2GAZK\[^D<_1+"D:TTI:HX?^"TX2+#G=G2<%^)CY MNH\*B#M."M!YP&6/"BS+WX>=!>AVYEMQE\6@*^N>[W9N;9\7=??\DE1]27M] MHVS]M?WUXDO;ZX&_OZB_?DFV/&(G]\,I\MW<"$9;[=SBT;NYI[UURZI;BXNK M:?9FU_!UW=ZBU>R]Y%+JCG#ZTIRUMX0O2=2T1[PNGSQJD[AH]XCOD\5V(=O7 M==LT;B^$9OO^J<7=(A"1M;2+/-)76ZPG#3G?-75'CO=7_R4EF4^P+4AWM2,9 MG[*LDF,SV:V>;R2B%J>$S%=*VDV !4"R3++JL!]W*KM'66<(-WA+WWC0?P4' M=IM &!4 JR,3S8=(9'0:^;-'S6QAPS.+86DU696>4)@1(7C0XZXFPIX0GIX/ MH=SW0Q@.V]MI1:_?A+'I4(&RW^ @P'H2\P\2F*.PJN-24KF.![H=WT//Z5CW MF1*T-6AV^+J9EN7M_ZN=2<_V"'.SN'$N!?XBB+2JH@LG$-.\;0,BLGX#-5+9 MO7#N>8D!$8;G9-1#N@-< 1O)2;]%:=_%:D DD?'?IA4U7)+R)S&C8W+*LZ\'9J%. 13[W7V&4:>LF8G=.:9Z:>1J&8-]# 8F^M_ M4Y%'W'J'+%#N@D2 =HA1X$B[':)PAA!63F"'94J3TZX+8'4!P*$R9PYYCZ5. M7)QLAG&5.BXX*-669;C,?.,+V3OHU9TFFU A/&.)L0**4*9?U5%:%WOF.FX?CI.D=BE!W(U:=2^\Q[+&^^4XE[O.D? M_,WX=]#TXPJY<7N!?D$/ZOLR5OVJ7_&VMM);U]CXEV0V6F\W47:C_91'6]![ M6FT)]5/ZG\U^RA:1Z^;2C'ALTK]ZY/X9)/K7DOX?4$L#!!0 ( %9VIE1 M5!J4/ , /L+ 0 :6YM+3(P,C(P-3 U+GAS9+56VW+:,!!];F?Z#ZK? MA6T(;2&03!LF*0FY3$C2)"\=82^@QI8<20[P]Y5\ 0*& &G]).^><[0K[:[= M.!R' 7H!(2EG3?/B+]-#YCC(XI!'X= MM;B'VZS/]]$%":&.3H"!((J+?71'@MA8^#$-0* C'D8!*-".=*$D"!]&4PV+9-?EMZH4N)B8)<=Q[7OSSO= M!&>EP/HXH.RI".[6:C4[\>;0)>2X)X)%]- M"?/@JITZ7T%I(?1+"J4YU(<%G 2O-. OMG9H?-E]WLNAL<0#0J(IO$]D+Y'- M' D<.RZNN#E%"K4,U\9B*%:3"&0A(745T-H7YU,"92'XT9"(D)A*->BR4W6J MNM\""(&I8R["%O1)'.BPGF,2T#X%WT**B $H4WHR(AZ\+9B7,&&,ZTK7[999 MC"V*J"YE;?C0,'=>%SR &QT^,@O=8ROEC=\^XGI46(CZ32M=&B$MFTCYT*>, M)OME_>0B;+HG-NGI94)IV(O@.8E8@G_)#I)U)$!J7I) 1QLR8@990?)(X,7! M=IQ9*(64S) ?U.SH\IZYACY*>JUNZJ!I26JFG979A@+Z34N?)LXOZ+?.K*0+ M)$<8Y36MEAS\XF%D^^821'A+*DNC0(OP"(2BNE;G^CV-G"I#OYK;!IE]I(7L M?Y!Q0'K;9JPI$/S'5#M&?S['K$/L68MD[XMMU-#9<\;$S8+>NA4AI+?Q;I-D',3F"[('+>#D&LG-9%$4U0;S&3=[E3 MB7@\9DI,D@PW+))Y2OZ2',?6-[/XS=_L4G)6>B'F-^ =Q5'\%[%K(*M+HV&G MFGKY%U!+ P04 " !6=J94/&)X[O\* !LAP % &EN;2TR,#(R,#4P M-5]L86(N>&ULS9U?4^NX&<;O.]/OH*8W['DP$YF6: DYVS; MGFU#IY*X@& ]K_S(^D62_TC^],-NDZ(7PK.$ MT?/1].CC"!$:L3BAZ_/1U\7X8C&;ST4Y(3 MD:!V?(;^>C0]P6@\'I#O-T)CQK_>SZM\'_/\.3N;3%Y?7X\H>\&OC#]E1Q'; M#,MPD>-\FU6Y?=Q]+']4^* M''_\.)W\X^?K1?1(-GB<4'G<(C+243(76]ST]/1T4J1J:4NY6_%4[^-DHNU4 M.8O4I$-?;";23F?R/@))6N-O,J@B6NS=X0G++ZD[W-M1GNR+[X[//\?"E"/=UZ$ M)5.XL:^::R-6>\77;9,Q9Y9B0Z6K.724P2 MD??Q]#]_D1_'ZF-1=/'O;S,F1@,7JRSG.,IU;D51SD>6](EI2RHON/:&>=13 MP%(QB9CHGI[S<:H.I0I_X&QCW6U95/- MU-U"1ZETM$F%0@ZK"!U_78R^+S3H5ZWZ]Z?)(1='E2V&0ML-H?E2Y&HI13/9 M557;3.F:KJ<%4=$60V8]:PF2&@^5?"%V'DL#5RE>6XI@I+NJ9JLM7<^-Q" J MVN;(K.E*@Z3(9U5_(5G$DVNQD;\G MZT1V-=*&/.A*HHCRQ=4+K%Z3UY M9KP+H:;,-3DVDR8P=4U0G%B,@7@H+5)BCU3\?2O.Y@E/][U@M)2NV0"LFG@8 MLJ (L7L#(:GD_CE9,\"TOV&QB5T3 QLVF6DK@Z(&M =R4T2@,B0L="Y?Y*A=#)T&%KBF]PE0 MRW870Y4X6(Q,AP-)*L*0C/-(4^V610]'+:5K@@"K)CN&+"AJ[-Y 7I0<%?HP M0+FD\2!,*IT?2 R;=D1*48" -)WUX2'4ON&X2K((I\K/E=B6=131HG4-"6C7 M!*4E# H6R!T(C K0W!0AWJ'Y)\%\&#(UI1]@6E;MN%2R &$QO?6A(O7>0)EM M.6\XAWL?6.KL9FZ/V>J^+J + I8>@,5C;W1)\R3?R^?Q;K:;%>&6 M K8EKOB S&DNS/0@> !,F1PH&9(ZI(3>:E_?5:"Y?! 2+)(I#>/ M!;#)0Z*>+^\A!=2[!:;'=I,;0!P0/MT. 8I$$&I&^89I3B/&GUGM<8D9VXK& M<#]C,3QBZ8ER"]:@(C3QZ@P)"+(A/@'4&J$?U#,MB,FY044&2.;@C;J+.!8' M*RO_7">43,%C8-6Z):S#;I,KBS @FF!W $.E\H/^@&0,NJ4A@7/\AN(>^P?G M>"@XQT&#<_P><):O+"!P3MY0W!/_X)P,!>^ ;5'K!IFW5"LU!%AXR+6]]P,@ .;Z1(;Y1*09;M_R.LY>$1O P&I)[@08P M;27'T(:'C]U@'T/5(%G'^0:I'*SW?EFTS$]KTS1I;VJ4)CQ0FL9Z&QFE]HW% M'>X\2;>+O2!B-6P%I:$,#Q>;O3YH5 P20;Y.NDMLY0T0ZW0U(]W= ME&.+K<.4XUIB$"#8'+6G'*NK*TKDHZHEJYQ@H&5H)CNK:(NIJIYK:6%4<]M0 MJY:+[[?0^/I"RY5ETKM'1N&'"]H25[4-F=,U;J8'4>N *;/F"QDJ=!ZOW,L5 M+C)[4UY+<];3FW:JCETG!%'#IIM6MZW3/=3H+SS)Q=YG;+/9TO+.D.T91$#G MJJ8[;>I:MXJ"(*#+F4E#J45-L0L%2@;[X6 M)-J*_G(_/5XMDSRUG7BV)<[Z)\!2C2$'M T^,_K?Z,=)0' M!&[8DF.YJ.UBOUFQ%%@)RZIR!4*'1:#-X X"*2&. 0>OY%!XR<9A718>;7,&TW? M6+JE.>;%''9N:Z$ G5MZ )M-:@Q10+38G0&45&*DU/XFA:O5*ZJ!EWIG$EA( M2.YXBGBG:6.FN%4;$#>=!J%YX^6:(X?QLHKR.)TS)_)=%\D+^8)S7/H#RPS) M74_@[#)MSMRT:0/"J-,@.%>SBI'+U6#-E==E:_A,#+_6K./I<\-RM&3H:T90_DC0 M9?E:O?K*]2H?GV])B2(YX4*-UFF,N0VC+K'S-Z: AEOO36DI@X"IUQ[\#I4J M ND0#^3<"I9Y_1RO,#+/R0:<2=$?XHJBH>8U2WWZ((@::-+DJ@AKGG@7@4A& M^EY5J;X@/SSL:X@@+6BH7'^_@;_U_+:K-(FN4H;AJS - MC>-5_-KVC 7\#H* *&B[@I;M*X2H4'ICX#.F3WS[G$?[.\XB0N336EG5XM?@,)#%JB6QX=:[^7[@I]\&%VN,,>BI\4C%@?Q M=IMGLD<5YN KYIU!CF]%#"B <4.B(R(@_ ;8A&Y.%)&H"/V 5#"J17L\;\L. MJQ.2^//^GCP0+N#BF"=YO8%!@/A6M] I8(;J M&:"5?,ZLS +]*C-!12ZV][37-UV+3V*SWB1^K7!&Q);_ E!+ P04 " !7 M=J94>L=36U8' #&6 % &EN;2TR,#(R,#4P-5]P&ULS9S?<^(V M$,??.]/_P:7/0""7MLDEO4FX<,-<+DD#=]?VY4;8 C21)2K) ?[[2C;F^&') MR\MM\I 0>R7M][-"]EJ2+]\M4QZ]4*69%%>-3NND$5$1RX2)Z57C\[!Y/>P- M!HU(&R(2PJ6@5PTA&^_^_/FGR/Y<_M)L1GU&>7(1O9=QM:M6*:P"H>&F$QO:CM9GJQ_BN*7G(GG"_=K3#2- M+"^A+Y::7355RK'C9QFF[=&=3LSW+ O9;GFAVH7/W[F1,3![VVF8BKX7[KUF: M-=VA9J?;/.VTECIIE/!S@DIR^D0GD?MKH[=IE8F4)O,942EQ,6N[\^V>M'W2 M.IN7G"DZN6I8.UM_MWMR=G+F:O]UQ\:LYK9K:N9Z5B-J[[0\5U1387*Q=_; M3A&Z-+9#T:2LR#5_A&^&&6>_[C&=J.FZ5Y;:YNS'PG+M2^D-E_&. ]R%0>Z) M+;MT#EO3N#65+^V$,@N]V_GOC?O8+#[F*.R_W_+&KL?:*!*;LC9.QI3G;7RS M-GLF[1_D64ED9&NM=FS78M^O[?A=JSB2*J'*,B_K(BK>B=IA+UU;M.=$V8J: M\8SQ3< G2J8^0FL:TN/H-BS;Q(\C>FU]2)P??4ZFU4CW3(!,.QA0*]5@4GU/ M=:S8W+&I@;MC"63<165J)3YGQV[KCK,'4'PV.$IP@0_BGFJ!%4 MBQB%:R$RPI_H7*H:^+N60.9O,)E7:4-$_5=&E*&*KR"T#XR!P,\P@7L4(C(? M*2(TA>C,;T4");XQ M!>=(^,#WY"'B[C,=$UYXU;?'=!AYA3D4.TIN6BL3'?T_E"@P^"UC*':4=+5& M(@+T7J;4CD/!$<9O#<6.DJC6B43@?BL,,RLW<7"?I>/O#UYW>1]:03FC)*<^ M46A\RR<3PK@YD1#C?4LH9Y2<-"0.C77/:E*$#T1"EQ_I*@3[P!1*&R47#C()#O$U!:$A0!@/*K8L9ZT9-IFHGU M2ATE)ZP7BD]_H'5&U;$QJ"@%C01*>@@5C3'FT#BSP^"JTQV/W"X>SXAS8 7E MC9(:^D0A\+V7(T7<1L+A*AU+[M^J4FD(I8R2" :D(8#>\:4:\9X)%"Y*!E@I M!W%\N%W&,R*FU+\RHMH2"ADE(PR)0QV+IZ"Q>'KD6(R2&?I$(?(MUJ?;;]?# MF+,I\>]P"Q8 [_O!I!Z0BK&W,-^&Y+:=JS3WI6\_5*/WF$*AXVSA#,G#P)TE MS-"D<*O/!!&Q3;TV>^X\F7Q]*6@0&+Y)DEI?(%J,KS7?"80K$CSD5ZY.&M]RP656^N1\7[ M1D+4?26@\!$G)<-B$=?"&>K\9B_T/3%D[64H!KX2T!@@3E"&Q:*NX5<]>S&: MRO!<_)XAE#CB$MQ*:6B@ARGA_";33% ='&?V#*&@$=?:5DI# WV;4C6U@]P' M)1=FMMY_&@+N*0 %C[BB-B@5+P#+[_O>B[UY0?H5UN W*B"B]XK$?&5('+N% M&L457B1$>^1_4$L! A0#% @ 5G:F5-3? MBI+#% &9$ !D ( ! &5A,34Y-30R+3AK7VEN;65D M<&AA#DY+3%?:6YM961P:&%R+FAT;5!+ 0(4 Q0 M ( %9VIE1 5!J4/ , /L+ 0 " ;8K !I;FTM,C R M,C U,#4N>'-D4$L! A0#% @ 5G:F5#QB>.[_"@ ;(< !0 M ( !("\ &EN;2TR,#(R,#4P-5]L86(N>&UL4$L! A0#% @ 5W:F M5'K'4UM6!P QE@ !0 ( !43H &EN;2TR,#(R,#4P-5]P <&UL4$L%!@ % 4 4P$ -E! $! end